Oliceridine Matches Sufentanil, Halves Nausea After Abdominal Surgery

This double-blind non-inferiority trial gives pharmacists head-to-head data on a G-protein-biased opioid for patient-controlled analgesia in high-risk postoperative intensive care patients.

oliceridinesufentanilopioidsmu-opioid agonistG-protein-biased agonistpostoperative analgesiaPCIAabdominal surgeryAICUpostoperative nauseanon-inferiority trialmultimodal analgesia Clinical Pharmacy Practice

Background Information

Oliceridine matches sufentanil for pain relief, reduces nausea.

Effective postoperative analgesia with fewer adverse effects can significantly improve patient recovery in intensive care settings. Oliceridine showed non-inferior pain control to sufentanil with significantly less nausea (9.6% vs 24.1%) among postoperative abdominal surgery patients. Oliceridine might be a preferable option for postoperative pain management in AICUs to reduce nausea, though further studies on broader populations may be needed. Oliceridine offers comparable analgesia to sufentanil with less nausea in postoperative care.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Li W, Zhao Y, Wang S, Li Y, Zhao Z, Zhao Y, Lang B, Zhao Y

Citation: Li W, Zhao Y, Wang S, et al. Oliceridine versus Sufentanil for Postoperative Intravenous Analgesia in Patients Undergoing Abdominal Surgery in the AICU: A Double-Blind Non-Inferiority Trial. Drug design, development and therapy. 2026;20:627542. doi:10.2147/DDDT.S627542

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →